Abivax: ABTECT enrollment complete, induction topline data expected in Q3
Abivax's phase 3 ABTECT trials, evaluating obefazimod in patients with moderate-to-severe UC, has completed the enrolment of a total of 1,275 patients (exceeding the target enrollment by 4%). Baseline patient characteristics of the phase 3 closely aligns with the previous phase 2b in terms of %prio
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.